$SYK · STRYKER CORP
Stryker reported Q3 2026 results with revenue of $6.5B (+7.7% organic) and adjusted EPS of $3.52 (+10.3% YoY). CEO Kevin Lobo acknowledged results "fell short of our expectations" despite double-digit adjusted earnings growth. The company trimmed full-year 2026 organic sales growth guidance to 6.5%-7.0% and adjusted EPS to $14.80-$14.90, while announcing a $3.0B increase to its share repurchase authorization.
- Q3 revenue $6.5B, organic growth 7.7% — CEO Kevin Lobo: "did fall short of our expectations"
- Adjusted EPS $3.52 (+10.3% YoY); GAAP EPS $1.96 (-11.7%) dragged by $293M goodwill/other impairments
- Full-year 2026 guidance: organic sales growth trimmed to 6.5%-7.0%, adjusted EPS $14.80-$14.90
- Board approved $3.0B increase to share repurchase program; $1.0B repurchased in Q3
- MedSurg and Neurotechnology organic growth 9.1%; Orthopaedics 5.9% — both driven by unit volume
Extended-hours trading shows SYK at $292.69, down 6.00% from the $311.36 regular close. The $119B market-cap giant is being penalized for the CEO's candid admission that results missed internal expectations, despite double-digit adjusted EPS growth and a $3B buyback authorization.
A $119B medtech leader admitting results missed internal expectations while cutting guidance is a rare and market-moving event, even with strong absolute numbers.
Stryker's 7.7% organic growth remains above medtech peers, but the guidance cut and CEO's candid disappointment contrast with competitor Zimmer Biomet's recent tone. The $3B buyback boost signals confidence in the balance sheet despite the operational miss.
$293M in goodwill and other impairments in Q3 (vs. $73M prior year) signals potential overpayment for past acquisitions. The March 2026 cybersecurity incident remains an ongoing risk factor cited in forward-looking statements.